| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 146, 688-694, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
U Ritthaler, Y Deng, Y Zhang, J Greten, M Abel, B Sido, J Allenberg, G Otto, H Roth and A Bierhaus
Department of Medicine, University of Heidelberg, Germany.
The cellular interactions of advanced glycation end products (AGEs), which have been hypothesized to contribute to the development of vascular lesions, occur, at least in part, through their binding to a novel integral membrane protein, the receptor for AGEs (RAGE). Studies of human vascular segments show that endothelial RAGE expression at the antigen and mRNA level was variable and usually at low levels in samples from healthy individuals. In contrast, patients with a range of peripheral occlusive vascular diseases, with or without underlying diabetes, demonstrated prominent enhancement of endothelial RAGE expression. Smooth muscle cells and nerves in the vessel wall showed constitutively high levels of RAGE expression that were unchanged with aging (from 1 to 92 years) or by the presence of vascular disease. These data suggest that RAGE is likely to have ligands other than AGEs, and that multiple factors in addition to AGEs impact on its expression. Taken together, our findings suggest that RAGE may contribute to the pathogenesis of a range of vascular disorders.
This article has been cited by other articles:
 |
|
 |
|
  L. Paczek, W. Michalska, and I. Bartlomiejczyk Trypsin, elastase, plasmin and MMP-9 activity in the serum during the human ageing process Age Ageing, May 1, 2008; 37(3): 318 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Toth, L. L. Rong, C. Yang, J. Martinez, F. Song, N. Ramji, V. Brussee, W. Liu, J. Durand, M. D. Nguyen, et al. Receptor for Advanced Glycation End Products (RAGEs) and Experimental Diabetic Neuropathy Diabetes, April 1, 2008; 57(4): 1002 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Marsche, M. Semlitsch, A. Hammer, S. Frank, B. Weigle, N. Demling, K. Schmidt, W. Windischhofer, G. Waeg, W. Sattler, et al. Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway FASEB J, April 1, 2007; 21(4): 1145 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Campo, P. Morbini, M. Zorzetto, C. Tinelli, E. Brunetta, C. Villa, C. Bombieri, M. Cuccia, C. Agostini, V. Bozzi, et al. Expression of Receptor for Advanced Glycation End Products in Sarcoid Granulomas Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 498 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jaulmes, S. Thierry, B. Janvier, M. Raymondjean, and V. Marechal Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1{beta} FASEB J, August 1, 2006; 20(10): 1727 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Y.L. Zee, J. R. Romero, J. L. Gould, D. A. Ricupero, and P. M Ridker Polymorphisms in the Advanced Glycosylation End Product-Specific Receptor Gene and Risk of Incident Myocardial Infarction or Ischemic Stroke Stroke, July 1, 2006; 37(7): 1686 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Schram, C. G. Schalkwijk, A. H. Bootsma, J. H. Fuller, N. Chaturvedi, C. D.A. Stehouwer, and on behalf of the EURODIAB Prospective Complication Advanced Glycation End Products Are Associated With Pulse Pressure in Type 1 Diabetes: The EURODIAB Prospective Complications Study Hypertension, July 1, 2005; 46(1): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Marx, D. Walcher, N. Ivanova, K. Rautzenberg, A. Jung, R. Friedl, V. Hombach, R. de Caterina, G. Basta, M.-P. Wautier, et al. Thiazolidinediones Reduce Endothelial Expression of Receptors for Advanced Glycation End Products Diabetes, October 1, 2004; 53(10): 2662 - 2668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Basta, A. M. Schmidt, and R. De Caterina Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes Cardiovasc Res, September 1, 2004; 63(4): 582 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Naka, L. G. Bucciarelli, T. Wendt, L. K. Lee, L. L. Rong, R. Ramasamy, S. F. Yan, and A. M. Schmidt RAGE Axis: Animal Models and Novel Insights Into the Vascular Complications of Diabetes Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zhou, K. Wang, M. S. Penn, S. P. Marso, M. A. Lauer, F. Forudi, X. Zhou, W. Qu, Y. Lu, D. M. Stern, et al. Receptor for AGE (RAGE) Mediates Neointimal Formation in Response to Arterial Injury Circulation, May 6, 2003; 107(17): 2238 - 2243. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wendt, N. Tanji, J. Guo, B. I. Hudson, A. Bierhaus, R. Ramasamy, B. Arnold, P. P. Nawroth, S. F. Yan, V. D'Agati, et al. Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1383 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Morcos, A. A.R. Sayed, A. Bierhaus, B. Yard, R. Waldherr, W. Merz, I. Kloeting, E. Schleicher, S. Mentz, R. F. Abd el Baki, et al. Activation of Tubular Epithelial Cells in Diabetic Nephropathy Diabetes, December 1, 2002; 51(12): 3532 - 3544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky Oxidative Stress and Stress-Activated Signaling Pathways: A Unifying Hypothesis of Type 2 Diabetes Endocr. Rev., October 1, 2002; 23(5): 599 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. F. Hou, J. P. Jiang, J. Q. Guo, G. B. Wang, X. Zhang, D. M. Stern, A. M. Schmidt, and W. F. Owen Jr. Receptor for Advanced Glycation End Products on Human Synovial Fibroblasts: Role in the Pathogenesis of Dialysis-Related Amyloidosis J. Am. Soc. Nephrol., May 1, 2002; 13(5): 1296 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Hudson, M. H. Stickland, P. J. Grant, and T. S. Futers Characterization of Allelic and Nucleotide Variation Between the RAGE Gene on Chromosome 6 and a Homologous Pseudogene Sequence to Its 5' Regulatory Region on Chromosome 3: Implications for Polymorphic Studies in Diabetes Diabetes, December 1, 2001; 50(12): 2646 - 2651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bierhaus, S. Schiekofer, M. Schwaninger, M. Andrassy, P. M. Humpert, J. Chen, M. Hong, T. Luther, T. Henle, I. Kloting, et al. Diabetes-Associated Sustained Activation of the Transcription Factor Nuclear Factor-{kappa}B Diabetes, December 1, 2001; 50(12): 2792 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. I. Hudson, M. H. Stickland, T. S. Futers, and P. J. Grant Effects of Novel Polymorphisms in the RAGE Gene on Transcriptional Regulation and Their Association With Diabetic Retinopathy Diabetes, June 1, 2001; 50(6): 1505 - 1511. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. Weindruch, K. P. Keenan, J. M. Carney, G. Fernandes, R. J. Feuers, R. A. Floyd, J. B. Halter, J. J. Ramsey, A. Richardson, G. S. Roth, et al. Caloric Restriction Mimetics: Metabolic Interventions J. Gerontol. A Biol. Sci. Med. Sci., March 1, 2001; 56(90001): 20 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. TANJI, G. S. MARKOWITZ, C. FU, T. KISLINGER, A. TAGUCHI, M. PISCHETSRIEDER, D. STERN, A. M. SCHMIDT, and V. D. D'AGATI Expression of Advanced Glycation End Products and Their Cellular Receptor RAGE in Diabetic Nephropathy and Nondiabetic Renal Disease J. Am. Soc. Nephrol., September 1, 2000; 11(9): 1656 - 1666. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Kislinger, C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan, M. Hofmann, S. F. Yan, M. Pischetsrieder, D. Stern, et al. Nepsilon -(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression J. Biol. Chem., October 29, 1999; 274(44): 31740 - 31749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Schmidt, S. D. Yan, J.-L. Wautier, and D. Stern Activation of Receptor for Advanced Glycation End Products : A Mechanism for Chronic Vascular Dysfunction in Diabetic Vasculopathy and Atherosclerosis Circ. Res., March 19, 1999; 84(5): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Liliensiek, M. Rocha, V. Umansky, A. Benner, J. Lin, R. Ziegler, P. P. Nawroth, and V. Schirrmacher Identification of Four Genes in Endothelial Cells Whose Expression Is Affected by Tumor Cells and Host Immune Status---A Study in Ex Vivo-Isolated Endothelial Cells Blood, November 1, 1998; 92(9): 3394 - 3404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lin, B. Liliensiek, M. Kanitz, U. Schimanski, H. Bohrer, R. Waldherr, E. Martin, G. Kauffmann, R. Ziegler, and P. P. Nawroth Molecular cloning of genes differentially regulated by TNF-{alpha} in bovine aortic endothelial cells, fibroblasts and smooth muscle cells Cardiovasc Res, June 1, 1998; 38(3): 802 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bierhaus, T. Illmer, M. Kasper, T. Luther, P. Quehenberger, H. Tritschler, P. Wahl, R. Ziegler, M. Muller, and P. P. Nawroth Advanced Glycation End Product (AGE)–Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE Circulation, October 7, 1997; 96(7): 2262 - 2271. [Abstract] [Full Text]
|
|
|
|
|
|
J. Li and A. M. Schmidt Characterization and Functional Analysis of the Promoter of RAGE, the Receptor for Advanced Glycation End Products J. Biol. Chem., June 27, 1997; 272(26): 16498 - 16506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Basta, G. Lazzerini, M. Massaro, T. Simoncini, P. Tanganelli, C. Fu, T. Kislinger, D. M. Stern, A. M. Schmidt, and R. De Caterina Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE: A Mechanism for Amplification of Inflammatory Responses Circulation, February 19, 2002; 105(7): 816 - 822. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
